NCT02300623View on ClinicalTrials.gov

Intermittent ART in Primary HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
HIV
Interventions
DRUG

Antiretroviral therapy plus Interleukin-2

Daily s.c. IL-2: 750,000 UI/m2/day for 6 months

DRUG

Antiretroviral therapy alone

Standard antiretroviral therapy

Trial Locations (1)

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors
lead

Juan A. Arnaiz

OTHER

NCT02300623 - Intermittent ART in Primary HIV Infection | Biotech Hunter | Biotech Hunter